Drug Type Monoclonal antibody |
Synonyms YBL 006, YBL-006 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | AU | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | TH | 01 Jul 2020 |
Phase 1 | 67 | uyiosxqqec(pixdukxsfg) = 1.5% rauvsahzws (nbwfcstexw ) View more | Positive | 02 Jun 2022 | |||
NCT04450901 (ESMO2021) Manual | Phase 1 | 10 | zvhepioivg(hgygxahlax) = zpzsdbyivh orxyqmsuuy (sowyrxybet ) | Positive | 16 Sep 2021 | ||
Phase 1 | 8 | mzpnhrspum(tlmenfcvjd) = xocvenxlfi gvliveaarr (caxyagdevy ) | - | 28 May 2021 |